SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. DCOY
5. SPY
6. MSFT
7. VKTX
8. PRGS
9. CMPX
10. GS

Go back to SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
(NASDAQ: SPRC) Delayed: 4.57 +0.04 (0.88%)
Previous Close $4.53    52 Week High $ 
Open $4.63    52 Week Low $ 
Day High $4.70    P/E N/A 
Day Low $4.50    EPS $ 
Volume 4,595       

(NASDAQ: SPRC) Delayed: 4.57 +0.04 (0.88%)
Previous Close $4.53    52 Week High $ 
Open $4.63    52 Week Low $ 
Day High $4.70    P/E N/A 
Day Low $4.50    EPS $ 
Volume 4,595